Cargando…

Long-lasting tumor response on short-time administration of vemurafenib—A case report

Detalles Bibliográficos
Autores principales:	Mitzel, Heidrun, Grabbe, Stephan, Loquai, Carmen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802569/ https://www.ncbi.nlm.nih.gov/pubmed/27075130 http://dx.doi.org/10.1016/j.jdcr.2014.10.003

Ejemplares similares

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
por: Krebs, Franziska K., et al.
Publicado: (2021)

Platelet-Derived GARP Induces Peripheral Regulatory T Cells—Potential Impact on T Cell Suppression in Patients with Melanoma-Associated Thrombocytosis
por: Zimmer, Niklas, et al.
Publicado: (2020)

B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells
por: Roos, Wynand P., et al.
Publicado: (2014)

Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report
por: Tzoulis, Charalampos, et al.
Publicado: (2015)

Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report
por: Broudic-Guibert, Morgane, et al.
Publicado: (2019)

Long-term survival of patients after ipilimumab and hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence matters
por: Schmidberger, Heinz, et al.
Publicado: (2018)

The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study
por: Haist, Maximilian, et al.
Publicado: (2022)

Vemurafenib and cutaneous adverse events - report of five cases
por: Silva, Giselle de Barros, et al.
Publicado: (2015)

Scurvy in a patient on vemurafenib
por: Gerstenblith, Meg R., et al.
Publicado: (2014)

Delayed-onset vemurafenib-induced panniculitis
por: Vance, Stephen L., et al.
Publicado: (2017)

A Rare Cause of Uveitis: Vemurafenib
por: Sızmaz, Selçuk, et al.
Publicado: (2018)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

Dupuytren’s contractures associated with the BRAF inhibitor vemurafenib: a case report
por: Chan, Sze Wai, et al.
Publicado: (2015)

An effective treatment in Erdheim Chester disease: vemurafenib: a case report
por: Bozan, Ersin, et al.
Publicado: (2023)

Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation
por: Moiseyenko, Fedor V., et al.
Publicado: (2019)

Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature
por: Heisig, Anne, et al.
Publicado: (2018)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation
por: Sahadudheen, K., et al.
Publicado: (2016)

Safety and efficacy of vemurafenib in end stage renal failure
por: Iddawela, Mahesh, et al.
Publicado: (2013)

Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report
por: Iafolla, Marco AJ, et al.
Publicado: (2019)

Screening for Distress in Routine Oncological Care—A Survey in 520 Melanoma Patients
por: Loquai, Carmen, et al.
Publicado: (2013)

Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration
por: Maximova, Natalia, et al.
Publicado: (2020)

Ruptured hepatic metastases of cutaneous melanoma during treatment with vemurafenib: an autopsy case report
por: Nosaka, Takuto, et al.
Publicado: (2015)

Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors—A Retrospective, Real-World Cohort Study
por: Haist, Maximilian, et al.
Publicado: (2021)

Role of Hypoxia and the Adenosine System in Immune Evasion and Prognosis of Patients with Brain Metastases of Melanoma: A Multiplex Whole Slide Immunofluorescence Study
por: Mayer, Arnulf, et al.
Publicado: (2020)

The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges
por: Stege, Henner, et al.
Publicado: (2021)

Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib
por: Castellani, Elisa, et al.
Publicado: (2012)

Orbital and chorioretinal manifestations of Erdheim-Chester disease treated with vemurafenib
por: Huang, Laura C., et al.
Publicado: (2018)

A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib
por: Maleka, A., et al.
Publicado: (2016)

Congenital fistula of the fourth branchial arch: Report of case with long‐lasting misdiagnosis
por: Stadler, Thomas M., et al.
Publicado: (2019)

Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma
por: Wolf, Sanne EJ, et al.
Publicado: (2013)

Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma
por: de Haan, Jorine, et al.
Publicado: (2018)

Short- and long-lasting behavioral and neurochemical adaptations: relationship with patterns of cocaine administration and expectation of drug effects in rats
por: Puig, S, et al.
Publicado: (2012)

Metastatic melanoma and vemurafenib: novel approaches
por: De Mello, Ramon Andrade
Publicado: (2012)

A STATement on Vemurafenib-Resistant Melanoma
por: Hartsough, Edward J., et al.
Publicado: (2013)

Complete remission of critical neurohistiocytosis by vemurafenib
por: Euskirchen, Philipp, et al.
Publicado: (2015)

The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
por: Cui, Hongmei, et al.
Publicado: (2021)

Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance
por: Peng, Jianyu, et al.
Publicado: (2023)

Long lasting clinical response to chemotherapy for advanced uterine leiomyosarcoma: a case report
por: Ridolfi, Claudio, et al.
Publicado: (2013)

Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
por: Aylwin, Simon J. B., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qbais7j77viug1nel77l5dujqn